Avalo Therapeutics, Inc.

AVTX

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001534120

SEC filings (opens in a new tab)

In the last 90 days, Avalo Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $1.31B in total; no superinvestor holds it.

Q1 2026 vs. Q4 2025

How the institutions holding Avalo Therapeutics, Inc. changed between Q4 2025 and Q1 2026.

All holders in Q1 2026 All holders in Q4 2025

13F holders of AVTX: Q4 2025 compared with Q1 2026
Measure	Q4 2025	Of which not filed for Q1 2026	Q1 2026	Change
Holders	84	1	97	+14
Shares	19.9M	804.1K	31.5M	+12.4M (+64.9%)
Value	$361.1M	$14.6M	$469.6M	+$123.0M (+35.5%)

1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.

New holders (33)

Institutions that held Avalo Therapeutics, Inc. at the end of Q1 2026 but not at the end of Q4 2025.

Institutions new to AVTX in Q1 2026
Institution	Shares	Value	% of portfolio
T. Rowe Price Investment Management, Inc.	2,162,684	$32.3M	0.02%
Avoro Capital Advisors LLC	1,410,000	$21.1M	0.21%
Farallon Capital Management, L.L.C.	916,000	$13.7M	0.08%
RTW Investments, LP	856,962	$12.8M	0.13%
Vanguard Capital Management LLC	719,694	$10.7M	0.00%
Kennedy Capital Management, Inc.	387,982	$5.79M	0.12%
DV Trading LLC	360,064	$5.38M	0.49%
Logos Global Management LP	300,000	$4.48M	0.23%
Pivotal bioVenture Partners Investment Advisor LLC	295,933	$4.42M	1.58%
Exome Asset Management LLC	159,341	$2.38M	1.40%
Vanguard Fiduciary Trust Co	86,434	$1.29M	0.00%
Rosalind Advisors, Inc.	75,000	$1.12M	0.46%
Acuta Capital Partners, LLC	60,808	$907.9K	0.65%
SEI Investments Co	56,854	$848.8K	0.00%
TD Asset Management Inc	51,408	$767.5K	0.00%
HRT Financial LP	48,105	$718.0K	0.00%
Man Group plc	46,553	$695.0K	0.00%
Dimensional Fund Advisors LP	40,821	$607.3K	0.00%
Prelude Capital Management, LLC	35,096	$524.0K	0.04%
EntryPoint Capital, LLC	30,041	$448.5K	0.13%
Aquatic Capital Management LLC	29,712	$443.6K	0.01%
Brevan Howard Capital Management LP	19,321	$288.5K	0.00%
Susquehanna Portfolio Strategies, LLC	17,227	$257.2K	0.00%
Westfield Capital Management Co LP	15,639	$233.5K	0.00%
AlphaCentric Advisors LLC	11,668	$174.2K	0.17%
Shay Capital LLC	10,166	$151.8K	0.02%
Charles Schwab Investment Management Inc	10,000	$149.3K	0.00%
Vanguard Global Advisers, LLC	5,605	$83.7K	0.00%
Royal Bank of Canada	216	$2.00K	0.00%
Farther Finance Advisors, LLC	75	$1.25K	0.00%
Fortitude Family Office, LLC	63	$941	0.00%
EverSource Wealth Advisors, LLC	35	$523	0.00%
Silver Grove Financial Group, Inc.	1	$15	0.00%

Sold out (19)

Institutions that held Avalo Therapeutics, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.

Institutions that sold out of AVTX in Q1 2026
Institution	Shares, Q4 2025	Value, Q4 2025
Silverarc Capital Management, LLC	524,436	$9.52M
Patient Square Capital LP	311,966	$5.67M
Jain Global LLC	217,292	$3.95M
Susquehanna International Group, LLP	210,994	$3.83M
SummitTX Capital, L.P.	195,873	$3.56M
Superstring Capital Management LP	153,313	$2.78M
Squadron Capital Management LLC	130,000	$2.36M
Fred Alger Management, LLC	80,092	$1.45M
Sio Capital Management, LLC	72,173	$1.31M
Woodline Partners LP	52,041	$945.1K
Atom Investors LP	51,194	$929.7K
Two Sigma Advisers, LP	49,400	$897.1K
Walleye Capital LLC	41,693	$757.1K
Ikarian Capital, LLC	31,106	$564.9K
Tower Research Capital LLC (TRC)	8,737	$158.7K
Belvedere Trading LLC	4,526	$82.2K
Acadian Asset Management LLC	1,471	$26.0K
Citigroup Inc	1,143	$20.8K
Group One Trading, L.P.	1	$18

Not filed for Q1 2026 yet (1)

Institutions that held Avalo Therapeutics, Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding AVTX in Q4 2025 that haven't filed for Q1 2026
Institution	Shares, Q4 2025	Value, Q4 2025
Vanguard Group Inc	804,084	$14.6M